137 related articles for article (PubMed ID: 16871275)
1. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Mesa RA; Tefferi A; Lasho TS; Loegering D; McClure RF; Powell HL; Dai NT; Steensma DP; Kaufmann SH
Leukemia; 2006 Oct; 20(10):1800-8. PubMed ID: 16871275
[TBL] [Abstract][Full Text] [Related]
2. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
4. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; Tefferi A
Haematologica; 2006 Mar; 91(3):415-6. PubMed ID: 16531268
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
Kalota A; Jeschke GR; Carroll M; Hexner EO
Clin Cancer Res; 2013 Apr; 19(7):1729-39. PubMed ID: 23386690
[TBL] [Abstract][Full Text] [Related]
7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
8. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
9. A case of myelofibrosis with myeloid metaplasia with JAK2(V617F) mutation who developed fibrous tumours in multiple organs.
Tabuchi T; Ohashi H; Fukami S; Susaki N; Kunishima S; Yokozawa T; Nagai H; Moritani S; Ichihara S; Saito H; Hamaguchi M
Eur J Haematol; 2006 Sep; 77(3):264-6. PubMed ID: 16923114
[No Abstract] [Full Text] [Related]
10. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
11. JAK2 in myeloproliferative disorders is not just another kinase.
Tefferi A; Gilliland DG
Cell Cycle; 2005 Aug; 4(8):1053-6. PubMed ID: 15970705
[TBL] [Abstract][Full Text] [Related]
12. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
13. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
14. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
15. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
[TBL] [Abstract][Full Text] [Related]
16. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
17. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
18. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
19. Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2.
Sakamoto E; Hato F; Kato T; Sakamoto C; Akahori M; Hino M; Kitagawa S
J Leukoc Biol; 2005 Jul; 78(1):301-9. PubMed ID: 15845643
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production.
Lee C; Lim HK; Sakong J; Lee YS; Kim JR; Baek SH
Mol Pharmacol; 2006 Mar; 69(3):1041-7. PubMed ID: 16354768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]